Jobs
-
The organizers of RDD 2014 have announced that the 2014 winner of the Charles G. Thiel Award is Dieter Hochrainer of Boehringer Ingelheim. The award was presented by Peter Byron at the opening of the… Read more . . .
-
According to an announcement from the Texas A&M Health Science Center (TAMHSC), Texas-based biotech Pulmotect has initiated clinical trials of PUL-042, an inhaled immune system stimulant. In 2012, the company received a grant of over… Read more . . .
-
The FDA has issued a Complete Response Letter (CRL) for Acorda Therapeutics’ Plumiaz diazepam nasal spray for the treatment of cluster seizures in epilepsy patients, the company has announced. Acorda submitted a 505(b)(2) application for… Read more . . .
-
Decision Resources Group says that a survey of US payers found that 90 percent said they would pay a premium for a new treatment that does a significantly better job of reducing asthma exacerbations than… Read more . . .
-
Less than a week after the approval of GSK’s Incruse Ellipta umeclidinium DPI in Europe, the company has announced that the FDA has approved the product for the treatment of COPD and it expects to… Read more . . .
-
At the recent Orlando Inhalation Conference, Bing Li of the FDA’s Division of Bioequivalence in the Office of Generic Drugs of the Center for Drug Evaluation and Research (CDER) offered practical advice for companies submitting… Read more . . .
-
Medivir has announced the launch of Adasuve inhaled loxapine for the treatment of agitation in schizophrenic or bipolar patients in Sweden, Norway, Finland, and Denmark. Medivir acquired the rights to commercialize Adasuve in all five… Read more . . .
-
The makers of a homeopathic capsaicin nasal spray are presenting a poster featuring “real-world patient case series analysis supporting the use of intranasal capsaicin as an effective rapid treatment for severe headache and migraine pain”… Read more . . .
-
Data from a 26-week head-to-head Phase 3 study show that the Ultibro Breezhaler indacaterol/glycopyrronium DPI produced greater improvement in the lung function of COPD patients with or without a history of moderate-to-severe exacerbations compared to… Read more . . .
-
GSK has announced that the European Commission has granted marketing authorization for its Incruse Ellipta umeclidinium DPI for the treatment of COPD with a dosage of 55 mcg. According to the company’s announcement, launches in… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.